Friday, September 16, 2016

BRIEF-Celgene Corp- releases data on Phase 2 RADIANCE trial

* Celgene Corp -Oral Ozanimod efficacy and safety results at

2 years from Phase 2 RADIANCE trial of patients with relapsing

multiple Sclerosis presented at 32nd Ectrims

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)